// App-Quantinova.ai

2525 : Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

Researchers

Presenter

  • Manuel Hidalgo

Principal Investigators

  • Christophe Massard

  • Lada Markovtsova

  • David Carlile

  • Angelika Lahr

  • Tapan Nayak

  • Katharina Lechner

  • Astrid Koehler

  • Ingrid Van Uffelen

  • Joan Albanell

  • Alvaro Taus

  • Marie-Paule Sablin

  • Andrea Varga

  • Ratislav Bahleda

  • Oliver Krieter

  • Maria Martinez Garcia

  • Valentina Boni

  • Emiliano Calvo

Medical Centers

  • START Madrid, CIOCC, Madrid, Spain

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • START Madrid, Centro Integral Oncologico Clara Campal, Hospital Universitario Norte Sanchinarro, Madrid, SpainDITEP, Drug Development Department, Institut Gustave Roussy, Villejuif, FranceRoche Diagnostics GmbH, Penzberg, Germany

  • Hospital Del Mar, Barcelona, Spain

  • Department of Medical Oncology, Institut Curie, Saint-Cloud, France

  • Medical Oncology, Hospital del Mar, Barcelona, Spain

  • Department of Medical Oncology, Institut Curie, Saint-Cloud, France

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Oncologia Medica. Hospital del Mar, Barcelona, Spain

Locations

  • Spain

  • Germany

  • United Kingdom

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • RO5520985

  • RG7221

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01688206

Sponsors

  • Roche

  • Hoffmann-La Roche

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved